Multicenter study of piroxicam in the treatment of acute musculoskeletal diseases involving 3011 patients.
An open non-comparative study was conducted to assess the efficacy and tolerability of piroxicam in patients with acute musculoskeletal disease. A total of 3011 patients of both sexes, aged between 18 and 70, were treated with piroxicam: 4 capsules (40 mg) after dinner, on the first two days and two capsules (20 mg) on the following days. Patients were evaluated for a maximum period of 14 days. Assessment of efficacy was made including local pain and limitation of mobility. The patients' self-assessment of pain was also analyzed. A clear improvement in each of the parameters analyzed was found by the third day of treatment. The general self-assessment of efficacy by the patients presented excellent and good results in 97.5%; very similar to the final assessment of efficacy made by the doctors, 91.1%. Adverse reactions were found in 368 patients (12.22%).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy*; D002062:Bursitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000188:drug therapy*; D010894:Piroxicam; D012737:Sex Factors; D013716:Tennis Elbow / Q000188:drug therapy; D013717:Tenosynovitis / Q000188:drug therapy; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D013843:Thiazines; D010894:Piroxicam